Digipath (Digipath) GF Value : $0.01 (As of Apr. 25, 2024)

View and export this data going back to 2011. Start your Free Trial

What is Digipath GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-04-25), Digipath's share price is $0.0329. Digipath's GF Value is $0.01. Therefore, Digipath's Price-to-GF-Value for today is 3.29.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Digipath is Significantly Overvalued.

Digipath (OTCPK:DIGP) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Digipath's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	0.0329	/	0.01
	=	3.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Digipath GF Value Related Terms

Thank you for viewing the detailed overview of Digipath's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Digipath (Digipath) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Digipath Inc (OTCPK:DIGP) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

6450 Cameron Street, Suite 113, Las Vegas, NV, USA, 89118

Website

https://www.digipath.com

DigiPath Inc is engaged in providing pharmaceutical-grade analysis and testing cannabis education and training and brings unbiased cannabis news coverage to the cannabis industry. It screens medicinal cannabis for potentially harmful contaminants, including solvents, pesticides, mold and yeast, heavy metals such as mercury, arsenic, cadmium, and others. It also tests cannabis for its quality, potency, and cannabinoid and terpene profiles, which determine the suitability of specific cannabis strains for the treatment of specific ailments.

Executives

A Stone Douglass	director	10200 WILLOW CREEK ROAD, SAN DIEGO CA 92131
Edmond Defrank	director	19360 RINALDI STREET, #448, NORTHRIDGE CA 91326
Kyle Remenda	officer: Chief Executive Officer	111-2532 SHORELINE DRIVE, LAKE COUNTRY A1 V4V2R6
Dennis Hartmann	director	1600 CAMDEN AVENUE, NO. 103, LOS ANGELES CA 90025
Bruce I Raben	director	430 VICTORIA TERRACE, RIDGEFIELD NJ 7657
Cindy Sue Orser	director	4507 APPLE WAY, BOULDER CO 80301
Alfredo Axtmayer	director	287 PAYNE DRIVE, CHESHIRE CT 06410
Joseph J Bianco	director	611 BROADWAY,, SUITE 307, NEW YORK NY 10012
Todd A Peterson	officer: Chief Financial Officer	3608 MALLARDWOOD DRIVE, LAS VEGAS NV 89129
Joe D Tanner	director	28720 ROADSIDE DRIVE, SUITE 128, AGOURA HILLS CA 91301
Raw Alternative, Llc	10 percent owner	16030 VENTURA BLVD. SUITE 380, ENCINO CA 91436
Todd Denkin	director, officer: President	C/O PHOTOTRON, INC., 20259 VENTURA BLVD., WOODLAND HILLS CA 91364
Barbee Denny Barbee	10 percent owner	3105 EAST CENTRAL, #114, WICHITA KS 67214
Eric Stoppenhagen	director, 10 percent owner, officer: CFO	8908 SPLITARROW DRIVE, AUSTIN TX 78717